Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products.

Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change.

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations.

This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.

As a massive federal hammer prepares to fall on the hemp industry, progressive states are throwing operators a regulatory lifeline—just as the legal cannabis market faces its own "Big Tobacco" reckoning.

A newly filed federal class-action lawsuit targets major Chicago-based operators like Cresco Labs and Green Thumb Industries, accusing them of "Big Tobacco"-style deceptive marketing that downplays the psychotropic risks of high-THC products.

Yet, against this turbulent backdrop, Midwestern lawmakers are aggressively reshaping the market. Facing a looming November 2026 federal ban on potent hemp products, Minnesota has enacted a landmark omnibus bill that allows hemp business owners to dual-license and pivot directly into the regulated cannabis market.

Similarly, Illinois lawmakers are advancing a massive industry overhaul (HB 5784) designed to ease financial burdens on smaller social equity operators while building parallel transitional pathways for hemp companies. By allowing these industries to consolidate, states are creating a vital legal gateway for hemp businesses to survive under the umbrella of the regulated cannabis market before federal workarounds vanish entirely.